{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T11:20:31Z","timestamp":1790680831424,"version":"4.1.0"},"reference-count":148,"publisher":"Elsevier","isbn-type":[{"value":"9780323899413","type":"print"}],"license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100005026","name":"Stichting Tegen Kanker","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009729","name":"Ludwig Institute for Cancer Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009729","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000923","name":"Australian Research Council","doi-asserted-by":"publisher","award":["16\/21-073"],"award-info":[{"award-number":["16\/21-073"]}],"id":[{"id":"10.13039\/501100000923","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002661","name":"Fonds De La Recherche Scientifique - FNRS","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002661","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022]]},"DOI":"10.1016\/bs.ircmb.2021.06.004","type":"book-chapter","created":{"date-parts":[[2022,2,9]],"date-time":"2022-02-09T23:10:28Z","timestamp":1644448228000},"page":"41-81","source":"Crossref","is-referenced-by-count":10,"title":["Targets in MPNs and potential therapeutics"],"prefix":"10.1016","member":"78","reference":[{"key":"10.1016\/bs.ircmb.2021.06.004_bb0010","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1182\/blood.V126.23.1491.1491","article-title":"BET inhibitor CPI-0610 is well tolerated and induces responses in diffuse large B-cell lymphoma and follicular lymphoma: preliminary analysis of an ongoing phase 1 study","volume":"126","author":"Abramson","year":"2015","journal-title":"Blood"},{"key":"10.1016\/bs.ircmb.2021.06.004_bb0015","doi-asserted-by":"crossref","first-page":"3779","DOI":"10.1182\/blood-2011-02-336743","article-title":"Efficacy of vorinostat in a murine model of polycythemia vera","volume":"119","author":"Akada","year":"2012","journal-title":"Blood"},{"key":"10.1016\/bs.ircmb.2021.06.004_bb0020","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1111\/bjh.12416","article-title":"A phase II study of vorinostat (MK-0683) in patients with polycythaemia vera and essential thrombocythaemia","volume":"162","author":"Andersen","year":"2013","journal-title":"Br. J. Haematol."},{"key":"10.1016\/bs.ircmb.2021.06.004_bb0025","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1158\/2159-8290.CD-11-0324","article-title":"Modulation of activation-loop phosphorylation by JAK inhibitors is binding mode dependent","volume":"2","author":"Andraos","year":"2012","journal-title":"Cancer Discov."},{"key":"10.1016\/bs.ircmb.2021.06.004_bb0030","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1182\/blood-2015-09-671172","article-title":"Activation of the thrombopoietin receptor by mutant calreticulin in CALR-mutant myeloproliferative neoplasms","volume":"127","author":"Araki","year":"2016","journal-title":"Blood"},{"key":"10.1016\/bs.ircmb.2021.06.004_bb0035","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1038\/nature13383","article-title":"Neuropathy of haematopoietic stem cell niche is essential for myeloproliferative neoplasms","volume":"512","author":"Arranz","year":"2014","journal-title":"Nature"},{"key":"10.1016\/bs.ircmb.2021.06.004_bb0040","doi-asserted-by":"crossref","first-page":"9555","DOI":"10.1074\/jbc.RA118.002836","article-title":"Tumor-associated calreticulin variants functionally compromise the peptide loading complex and impair its recruitment of MHC-I","volume":"293","author":"Arshad","year":"2018","journal-title":"J. Biol. Chem."},{"key":"10.1016\/bs.ircmb.2021.06.004_bb0045","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1056\/NEJMoa1503479","article-title":"Telomerase inhibitor imetelstat in patients with essential thrombocythemia","volume":"373","author":"Baerlocher","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/bs.ircmb.2021.06.004_bb0050","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1038\/s41375-019-0538-1","article-title":"Knock-in of murine Calr del52 induces essential thrombocythemia with slow-rising dominance in mice and reveals key role of Calr exon 9 in cardiac development","volume":"34","author":"Balligand","year":"2019","journal-title":"Leukemia"},{"key":"10.1016\/bs.ircmb.2021.06.004_bb0055","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1038\/nsmb.2348","article-title":"Crystal structures of the JAK2 pseudokinase domain and the pathogenic mutant V617F","volume":"19","author":"Bandaranayake","year":"2012","journal-title":"Nat. Struct. Mol. Biol."},{"key":"10.1016\/bs.ircmb.2021.06.004_bb0060","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1038\/s41375-018-0077-1","article-title":"Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet","volume":"32","author":"Barbui","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/bs.ircmb.2021.06.004_bb0065","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1111\/jcmm.12162","article-title":"Co-targeting the PI3K\/mTOR and JAK2 signalling pathways produces synergistic activity against myeloproliferative neoplasms","volume":"17","author":"Bartalucci","year":"2013","journal-title":"J. Cell. Mol. Med."},{"key":"10.1016\/bs.ircmb.2021.06.004_bb0070","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(05)71142-9","article-title":"Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders","volume":"365","author":"Baxter","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/bs.ircmb.2021.06.004_bb0075","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/nrc3256","article-title":"BET domain co-regulators in obesity, inflammation and cancer","volume":"12","author":"Belkina","year":"2012","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/bs.ircmb.2021.06.004_bb0080","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdy048","article-title":"A phase I study of CPI-0610, a bromodomain and extra terminal protein (BET) inhibitor in patients with relapsed or refractory lymphoma","volume":"29","author":"Blum","year":"2018","journal-title":"Ann. Oncol."},{"key":"10.1016\/bs.ircmb.2021.06.004_bb0085","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/HS9.0000000000000404","article-title":"25th congress of the European Hematology Association virtual edition, 2020","volume":"4","author":"Abstract Book","year":"2020","journal-title":"HemaSphere"},{"key":"10.1016\/bs.ircmb.2021.06.004_bb0095","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1182\/blood-2015-07-661983","article-title":"Presence of atypical thrombopoietin receptor (MPL) mutations in triple-negative essential thrombocythemia patients","volume":"127","author":"Cabagnols","year":"2016","journal-title":"Blood"},{"key":"10.1016\/bs.ircmb.2021.06.004_bb0100","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1056\/NEJMoa1910182","article-title":"A phase 3 trial of Luspatercept in patients with transfusion-dependent \u03b2-thalassemia","volume":"382","author":"Cappellini","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/bs.ircmb.2021.06.004_bb0105","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1182\/blood-2015-11-681932","article-title":"Thrombopoietin receptor activation by myeloproliferative neoplasm associated calreticulin mutants","volume":"127","author":"Chachoua","year":"2016","journal-title":"Blood"},{"key":"10.1016\/bs.ircmb.2021.06.004_bb0110","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1111\/jcmm.12156","article-title":"Combination treatment for myeloproliferative neoplasms using JAK and pan-class I PI3K inhibitors","volume":"17","author":"Choong","year":"2013","journal-title":"J. Cell. Mol. Med."},{"key":"10.1016\/bs.ircmb.2021.06.004_bb0115","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40164-019-0157-6","article-title":"The SMAC mimetic LCL-161 selectively targets JAK2V617F mutant cells","volume":"9","author":"Craver","year":"2020","journal-title":"Exp. Hematol. Oncol."},{"key":"10.1016\/bs.ircmb.2021.06.004_bb0120","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1038\/leu.2013.338","article-title":"Recurrent mutations, including NPM1c, activate a BRD4-dependent core transcriptional program in acute myeloid leukemia","volume":"28","author":"Dawson","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/bs.ircmb.2021.06.004_bb0125","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.1073\/pnas.1211560110","article-title":"Tryptophan at the transmembrane-cytosolic junction modulates thrombopoietin receptor dimerization and activation","volume":"110","author":"Defour","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/bs.ircmb.2021.06.004_bb0130","doi-asserted-by":"crossref","first-page":"4198","DOI":"10.1182\/blood-2003-10-3471","article-title":"Familial essential thrombocythemia associated with a dominant-positive activating mutation of the c-MPL gene, which encodes for the receptor for thrombopoietin","volume":"103","author":"Ding","year":"2004","journal-title":"Blood"},{"key":"10.1016\/bs.ircmb.2021.06.004_bb0135","doi-asserted-by":"crossref","first-page":"3325","DOI":"10.1182\/blood-2008-04-149047","article-title":"The Asn505 mutation of the c-MPL gene, which causes familial essential thrombocythemia, induces autonomous homodimerization of the c-Mpl protein due to strong amino acid polarity","volume":"114","author":"Ding","year":"2009","journal-title":"Blood"},{"key":"10.1016\/bs.ircmb.2021.06.004_bb0140","doi-asserted-by":"crossref","first-page":"2350","DOI":"10.1073\/pnas.94.6.2350","article-title":"Dissecting the thrombopoietin receptor: functional elements of the Mpl cytoplasmic domain","volume":"94","author":"Drachman","year":"1997","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/bs.ircmb.2021.06.004_bb0145","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1182\/blood-2006-10-054940","article-title":"The JAK2 617V>F mutation triggers erythropoietin hypersensitivity and terminal erythroid amplification in primary cells from patients with polycythemia vera","volume":"110","author":"Dupont","year":"2007","journal-title":"Blood"},{"key":"10.1016\/bs.ircmb.2021.06.004_bb0150","doi-asserted-by":"crossref","first-page":"e11157","DOI":"10.1371\/journal.pone.0011157","article-title":"JAK2 V617F constitutive activation requires JH2 residue F595: a pseudokinase domain target for specific inhibitors","volume":"5","author":"Dusa","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/bs.ircmb.2021.06.004_bb0155","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1158\/2159-8290.CD-15-1434","article-title":"Mutant calreticulin requires both its mutant C-terminus and the thrombopoietin receptor for oncogenic transformation","volume":"6","author":"Elf","year":"2016","journal-title":"Cancer Discov."},{"key":"10.1016\/bs.ircmb.2021.06.004_bb0160","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1186\/s13045-019-0811-9","article-title":"LSD1\/KDM1A inhibitors in clinical trials: advances and prospects","volume":"12","author":"Fang","year":"2019","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/bs.ircmb.2021.06.004_bb0165","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1182\/blood-2015-07-661835","article-title":"Whole-exome sequencing identifies novel MPL and JAK2 mutations in triple-negative myeloproliferative neoplasms","volume":"127","author":"Feenstra","year":"2016","journal-title":"Blood"},{"key":"10.1016\/bs.ircmb.2021.06.004_bb0170","doi-asserted-by":"crossref","first-page":"e38089","DOI":"10.7554\/eLife.38089","article-title":"Receptor-mediated dimerization of JAK2 FERM domains is required for JAK2 activation","volume":"7","author":"Ferrao","year":"2018","journal-title":"Elife"},{"key":"10.1016\/bs.ircmb.2021.06.004_bb0175","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1182\/blood-2017-08-802165","article-title":"Ruxolitinib in ET: not all MPN are equal","volume":"130","author":"Finazzi","year":"2017","journal-title":"Blood"},{"key":"10.1016\/bs.ircmb.2021.06.004_bb0180","doi-asserted-by":"crossref","first-page":"7347","DOI":"10.1158\/1078-0432.CCR-11-1541","article-title":"Heat shock protein 90 inhibitor is synergistic with JAK2 inhibitor and overcomes resistance to JAK2-TKI in human myeloproliferative neoplasm cells","volume":"17","author":"Fiskus","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/bs.ircmb.2021.06.004_bb0185","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1158\/1535-7163.MCT-14-0258","article-title":"BET protein antagonist JQ1 is synergistically lethal with FLT3 tyrosine kinase inhibitor (TKI) and overcomes resistance to FLT3-TKI in AML cells expressing FLT-ITD","volume":"13","author":"Fiskus","year":"2014","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/bs.ircmb.2021.06.004_bb0190","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1158\/1535-7163.MCT-13-0770","article-title":"Highly active combination of BRD4 antagonist and histone deacetylase inhibitor against human acute myelogenous leukemia cells","volume":"13","author":"Fiskus","year":"2014","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/bs.ircmb.2021.06.004_bb0195","doi-asserted-by":"crossref","first-page":"6392","DOI":"10.1182\/blood-2011-04-348144","article-title":"TNF\u03b1 facilitates clonal expansion of JAK2V617F positive cells in myeloproliferative neoplasms","volume":"118","author":"Fleischman","year":"2011","journal-title":"Blood"},{"key":"10.1016\/bs.ircmb.2021.06.004_bb0200","doi-asserted-by":"crossref","first-page":"2833","DOI":"10.1182\/blood.V122.21.2833.2833","article-title":"Ruxolitinib discontinuation in patients with myelofibrosis: an analysis from clinical practice","volume":"122","author":"Fonseca","year":"2013","journal-title":"Blood"},{"key":"10.1016\/bs.ircmb.2021.06.004_bb0205","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/s41408-018-0167-3","article-title":"A prospective evaluation of vitamin B1 (thiamine) level in myeloproliferative neoplasms: clinical correlations and impact of JAK2 inhibitor therapy","volume":"9","author":"Gangat","year":"2019","journal-title":"Blood Cancer J."},{"key":"10.1016\/bs.ircmb.2021.06.004_bb0210","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.3324\/haematol.2011.061390","article-title":"Experience with PEGylated interferon -2a in advanced myeloproliferative neoplasms in an international cohort of 118 patients","volume":"97","author":"Gowin","year":"2012","journal-title":"Haematologica"},{"key":"10.1016\/bs.ircmb.2021.06.004_bb0215","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2020.100712","article-title":"A p53-JAK-STAT connection involved in myeloproliferative neoplasm pathogenesis and progression to secondary acute myeloid leukemia","volume":"42","author":"Goyal","year":"2020","journal-title":"Blood Rev."},{"key":"10.1016\/bs.ircmb.2021.06.004_bb0220","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3324\/haematol.2014.113845","article-title":"Molecular determinants of pathogenesis and clinical phenotype in myeloproliferative neoplasms","volume":"102","author":"Grinfeld","year":"2017","journal-title":"Haematologica"},{"key":"10.1016\/bs.ircmb.2021.06.004_bb0225","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1056\/NEJMoa1716614","article-title":"Classification and personalized prognosis in myeloproliferative neoplasms","volume":"379","author":"Grinfeld","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/bs.ircmb.2021.06.004_bb0230","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1038\/sj.leu.2405049","article-title":"The histone deacetylase inhibitor ITF2357 selectively targets cells bearing mutated JAK2V617F","volume":"22","author":"Guerini","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/bs.ircmb.2021.06.004_bb0235","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1182\/blood.2019001057","article-title":"Lack of Gdf11 does not improve anemia or prevent the activity of RAP-536 in a mouse model of beta-thalassemia","volume":"134","author":"Guerra","year":"2019","journal-title":"Blood"},{"key":"10.1016\/bs.ircmb.2021.06.004_bb0240","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1016\/j.jaci.2018.07.022","article-title":"Janus kinase 2 activation mechanisms revealed by analysis of suppressing mutations","volume":"143","author":"Hammar\u00e9n","year":"2018","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/bs.ircmb.2021.06.004_bb0245","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1056\/NEJMoa1110556","article-title":"JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis","volume":"366","author":"Harrison","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/bs.ircmb.2021.06.004_bb0250","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1182\/blood.V122.21.661.661","volume":"122","author":"Harrison","year":"2013","journal-title":"Blood"},{"key":"10.1016\/bs.ircmb.2021.06.004_bb0255","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1182\/blood-2017-05-785790","article-title":"Ruxolitinib vs best available therapy for ET intolerant or resistant to hydroxycarbamide","volume":"130","author":"Harrison","year":"2017","journal-title":"Blood"},{"key":"10.1016\/bs.ircmb.2021.06.004_bb0260","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1182\/blood-2019-129288","article-title":"Fedratinib induces spleen responses and reduces symptom burden in patients with myeloproliferative neoplasm (MPN)-associated myelofibrosis (MF) and low platelet counts, who were either ruxolitinib-Na\u00efve or were previously treated with ruxolitinib","volume":"134","author":"Harrison","year":"2019","journal-title":"Blood"},{"key":"10.1016\/bs.ircmb.2021.06.004_bb0265","doi-asserted-by":"crossref","first-page":"4175","DOI":"10.1182\/blood-2019-129245","volume":"134","author":"Harrison","year":"2019","journal-title":"Blood"},{"key":"10.1016\/bs.ircmb.2021.06.004_bb0270","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1182\/blood-2019-130158","article-title":"Results from a phase 2 study of Navitoclax in combination with ruxolitinib in patients with primary or secondary myelofibrosis","volume":"134","author":"Harrison","year":"2019","journal-title":"Blood"},{"key":"10.1016\/bs.ircmb.2021.06.004_bb0275","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1038\/nature03546","article-title":"A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera","volume":"434","author":"James","year":"2005","journal-title":"Nature"},{"key":"10.1016\/bs.ircmb.2021.06.004_bb0280","doi-asserted-by":"crossref","first-page":"6257","DOI":"10.1158\/0008-5472.CAN-18-0338","article-title":"Dose and schedule determine distinct molecular mechanisms underlying the efficacy of the p53\u2013MDM2 inhibitor HDM201","volume":"78","author":"Jeay","year":"2018","journal-title":"Cancer Res."},{"issue":"3","key":"10.1016\/bs.ircmb.2021.06.004_bb0285","doi-asserted-by":"crossref","first-page":"e54","DOI":"10.1097\/HS9.0000000000000054","article-title":"LSD1 inhibition prolongs survival in mouse models of MPN by selectively targeting the disease clone","volume":"2","author":"Jutzi","year":"2018","journal-title":"Hemasphere"},{"key":"10.1016\/bs.ircmb.2021.06.004_bb0290","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1056\/NEJMoa1311347","article-title":"Somatic mutations of calreticulin in myeloproliferative neoplasms","volume":"369","author":"Klampfl","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/bs.ircmb.2021.06.004_bb0295","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1158\/2159-8290.CD-14-0736","article-title":"JAK-STAT pathway activation in malignant and nonmalignant cells contributes to MPN pathogenesis and therapeutic response","volume":"5","author":"Kleppe","year":"2015","journal-title":"Cancer Discov."},{"key":"10.1016\/bs.ircmb.2021.06.004_bb0300","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/j.ccell.2018.03.024","article-title":"Dual targeting of oncogenic activation and inflammatory signaling increases therapeutic efficacy in myeloproliferative neoplasms","volume":"33","author":"Kleppe","year":"2018","journal-title":"Cancer Cell"},{"key":"10.1016\/bs.ircmb.2021.06.004_bb0305","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/nature11303","article-title":"Heterodimeric JAK-STAT activation as a mechanism of persistence to JAK2 inhibitor therapy","volume":"489","author":"Koppikar","year":"2012","journal-title":"Nature"},{"key":"10.1016\/bs.ircmb.2021.06.004_bb0310","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1038\/leu.2016.12","article-title":"Myeloproliferative neoplasms and inflammation: whether to target the malignant clone or the inflammatory process or both","volume":"30","author":"Koschmieder","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/bs.ircmb.2021.06.004_bb0315","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1056\/NEJMoa051113","article-title":"A gain-of-function mutation of JAK2 in myeloproliferative disorders","volume":"352","author":"Kralovics","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/bs.ircmb.2021.06.004_bb0320","doi-asserted-by":"crossref","first-page":"3347","DOI":"10.1182\/blood-2014-10-608315","article-title":"Impact of allogeneic stem cell transplantation on survival of patients less than 65 years of age with primary myelofibrosis","volume":"125","author":"Kr\u00f6ger","year":"2015","journal-title":"Blood"},{"key":"10.1016\/bs.ircmb.2021.06.004_bb0325","doi-asserted-by":"crossref","first-page":"3509","DOI":"10.1200\/JCO.2020.38.15_suppl.3509","article-title":"First-in-human study of palcitoclax (APG-1252), a novel dual Bcl-2\/Bcl-xL inhibitor, demonstrated advantages in platelet safety while maintaining anticancer effect in U.S. patients with metastatic solid tumors","volume":"38","author":"Lakhani","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/bs.ircmb.2021.06.004_bb0330","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1038\/leu.2017.43","article-title":"Rethinking JAK2 inhibition: towards novel strategies of more specific and versatile Janus kinase inhibition","volume":"31","author":"Leroy","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/bs.ircmb.2021.06.004_bb0335","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1042\/BCJ20160085","article-title":"Uncoupling JAK2 V617F activation from cytokine-induced signalling by modulation of JH2 alphaC helix","volume":"473","author":"Leroy","year":"2016","journal-title":"Biochem. J."},{"key":"10.1016\/bs.ircmb.2021.06.004_bb0340","doi-asserted-by":"crossref","first-page":"2974","DOI":"10.1074\/jbc.M115.696534","article-title":"His499 regulates dimerization and prevents oncogenic activation by asparagine mutations of the human thrombopoietin receptor","volume":"291","author":"Leroy","year":"2016","journal-title":"J. Biol. Chem."},{"issue":"Suppl. 1","key":"10.1016\/bs.ircmb.2021.06.004_bb0090","doi-asserted-by":"crossref","first-page":"S20","DOI":"10.1186\/1755-1536-5-S1-S20","article-title":"Primary myelofibrosis and the \u201cbad seeds in bad soil\u201d concept","volume":"5","author":"Le Bousse-Kerdil\u00e8s","year":"2012","journal-title":"Fibrogenesis Tissue Repair"},{"issue":"1","key":"10.1016\/bs.ircmb.2021.06.004_bb0345","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.jaci.2018.12.1023","article-title":"Differential effect of inhibitory strategies of the V617 mutant of JAK2 on cytokine receptor signaling","volume":"144","author":"Leroy","year":"2019","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/bs.ircmb.2021.06.004_bb0350","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.ccr.2005.03.023","article-title":"Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis","volume":"7","author":"Levine","year":"2005","journal-title":"Cancer Cell"},{"key":"10.1016\/bs.ircmb.2021.06.004_bb0355","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1097\/01.HS9.0000564036.35865.de","article-title":"A novel activating TPOR mutation in essential thrombocytopenia points to an activating effect of tryptophan and aromatics at the outset of the transmembrane domain","volume":"3","author":"Levy","year":"2019","journal-title":"HemaSphere"},{"key":"10.1016\/bs.ircmb.2021.06.004_bb0360","doi-asserted-by":"crossref","first-page":"3139","DOI":"10.1182\/blood-2013-06-510222","article-title":"JAK2V617F homozygosity drives a phenotypic switch in myeloproliferative neoplasms, but is insufficient to sustain disease","volume":"123","author":"Li","year":"2014","journal-title":"Blood"},{"key":"10.1016\/bs.ircmb.2021.06.004_bb0365","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1080\/17474086.2018.1436965","article-title":"GATA1 insufficiencies in primary myelofibrosis and other hematopoietic disorders: consequences for therapy","volume":"11","author":"Ling","year":"2018","journal-title":"Expert Rev. Hematol."},{"key":"10.1016\/bs.ircmb.2021.06.004_bb0370","doi-asserted-by":"crossref","first-page":"4284","DOI":"10.1182\/blood-2010-04-279125","article-title":"Treatment with the Bcl-xL inhibitor ABT-737 in combination with interferon \u03b1 specifically targets JAK2V617F-positive polycythemia vera hematopoietic progenitor cells","volume":"116","author":"Lu","year":"2010","journal-title":"Blood"},{"key":"10.1016\/bs.ircmb.2021.06.004_bb0375","doi-asserted-by":"crossref","first-page":"3098","DOI":"10.1182\/blood-2012-02-410712","article-title":"Combination treatment in vitro with Nutlin, a small-molecule antagonist of MDM2, and PEGylated interferon-\u03b1 2a specifically targets JAK2V617F-positive polycythemia vera cells","volume":"120","author":"Lu","year":"2012","journal-title":"Blood"},{"key":"10.1016\/bs.ircmb.2021.06.004_bb0380","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1182\/blood-2013-11-537167","article-title":"Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms","volume":"123","author":"Lundberg","year":"2014","journal-title":"Blood"},{"key":"10.1016\/bs.ircmb.2021.06.004_bb0385","doi-asserted-by":"crossref","first-page":"255","DOI":"10.3389\/fonc.2018.00255","article-title":"Lysine-specific demethylase 1A as a promising target in acute myeloid leukemia","volume":"8","author":"Magliulo","year":"2018","journal-title":"Front. Oncol."},{"key":"10.1016\/bs.ircmb.2021.06.004_bb0390","doi-asserted-by":"crossref","first-page":"4005","DOI":"10.1111\/jcmm.13753","article-title":"Increased Dkk-1 plasma levels may discriminate disease subtypes in myeloproliferative neoplasms","volume":"22","author":"Mambet","year":"2018","journal-title":"J. Cell. Mol. Med."},{"key":"10.1016\/bs.ircmb.2021.06.004_bb0395","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s40265-019-01251-5","article-title":"Luspatercept: first approval","volume":"80","author":"Markham","year":"2020","journal-title":"Drugs"},{"key":"10.1016\/bs.ircmb.2021.06.004_bb0400","doi-asserted-by":"crossref","first-page":"5401","DOI":"10.1073\/pnas.92.12.5401","article-title":"Interferon gamma signals via a high-affinity multisubunit receptor complex that contains two types of polypeptide chain","volume":"92","author":"Marsters","year":"1995","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/bs.ircmb.2021.06.004_bb0405","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1182\/blood-2009-12-257063","article-title":"Myeloproliferative neoplasm induced by constitutive expression of JAK2V617F in knock-in mice","volume":"116","author":"Marty","year":"2010","journal-title":"Blood"},{"key":"10.1016\/bs.ircmb.2021.06.004_bb0410","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1182\/blood-2013-05-504555","article-title":"Germ-line JAK2 mutations in the kinase domain are responsible for hereditary thrombocytosis and are resistant to JAK2 and HSP90 inhibitors","volume":"123","author":"Marty","year":"2014","journal-title":"Blood"},{"key":"10.1016\/bs.ircmb.2021.06.004_bb0415","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1182\/blood-2015-11-679571","article-title":"Calreticulin mutants in mice induce an MPL-dependent thrombocytosis with frequent progression to myelofibrosis","volume":"127","author":"Marty","year":"2016","journal-title":"Blood"},{"key":"10.1016\/bs.ircmb.2021.06.004_bb0420","first-page":"254","article-title":"Open label phase I study of single agent Oral RG7388 (idasanutlin) in patients with polycythemia vera and essential thrombocythemia","volume":"130","author":"Mascarenhas","year":"2017","journal-title":"Blood"},{"key":"10.1016\/bs.ircmb.2021.06.004_bb0425","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1001\/jamaoncol.2017.5818","article-title":"Pacritinib vs best available therapy, including ruxolitinib, in patients with myelofibrosis: a randomized clinical trial","volume":"4","author":"Mascarenhas","year":"2018","journal-title":"JAMA Oncol."},{"key":"10.1016\/bs.ircmb.2021.06.004_bb0430","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1182\/blood-2019-127119","article-title":"MANIFEST, a phase 2 study of CPI-0610, a bromodomain and extraterminal domain inhibitor (BETi), as monotherapy or \"add-on\" to ruxolitinib, in patients with refractory or intolerant advanced myelofibrosis","volume":"134","author":"Mascarenhas","year":"2019","journal-title":"Blood"},{"key":"10.1016\/bs.ircmb.2021.06.004_bb0435","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1182\/blood.2018893545","article-title":"Oral idasanutlin in patients with polycythemia vera","volume":"134","author":"Mascarenhas","year":"2019","journal-title":"Blood"},{"key":"10.1016\/bs.ircmb.2021.06.004_bb0440","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1016\/j.cell.2007.01.037","article-title":"Programmed anuclear cell death delimits platelet life span","volume":"128","author":"Mason","year":"2007","journal-title":"Cell"},{"issue":"5","key":"10.1016\/bs.ircmb.2021.06.004_bb0445","doi-asserted-by":"crossref","first-page":"e225","DOI":"10.1016\/S2352-3026(17)30027-3","article-title":"Pacritinib versus best available therapy for the treatment of myelofibrosis irrespective of baseline cytopenias (PERSIST-1): an international, randomised, phase 3 trial","volume":"4","author":"Mesa","year":"2017","journal-title":"Lancet Haematol."},{"key":"10.1016\/bs.ircmb.2021.06.004_bb0450","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.ccell.2015.06.006","article-title":"CHZ868, a type II JAK2 inhibitor, reverses type I JAK inhibitor persistence and demonstrates efficacy in myeloproliferative neoplasms","volume":"28","author":"Meyer","year":"2015","journal-title":"Cancer Cell"},{"key":"10.1016\/bs.ircmb.2021.06.004_bb0455","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1042\/BJ20081847","article-title":"Calreticulin, a multi-process calcium-buffering chaperone of the endoplasmic reticulum","volume":"417","author":"Michalak","year":"2009","journal-title":"Biochem. J."},{"key":"10.1016\/bs.ircmb.2021.06.004_bb0460","doi-asserted-by":"crossref","first-page":"3913","DOI":"10.1182\/blood-2006-03-008805","article-title":"Molecular mimicry in the chronic myeloproliferative disorders: reciprocity between quantitative JAK2 V617F and Mpl expression","volume":"108","author":"Moliterno","year":"2006","journal-title":"Blood"},{"key":"10.1016\/bs.ircmb.2021.06.004_bb0465","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1016\/j.cell.2015.02.011","article-title":"Tuning cytokine receptor signaling by re-orienting dimer geometry with surrogate ligands","volume":"160","author":"Moraga","year":"2015","journal-title":"Cell"},{"key":"10.1016\/bs.ircmb.2021.06.004_bb0470","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1038\/onc.2011.313","article-title":"JAK2(V617F) negatively regulates p53 stabilization by enhancing MDM2 via La expression in myeloproliferative neoplasms","volume":"31","author":"Nakatake","year":"2011","journal-title":"Oncogene"},{"key":"10.1016\/bs.ircmb.2021.06.004_bb0475","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.1182\/blood-2017-06-782037","article-title":"Myeloproliferative neoplasms: from origins to outcomes","volume":"130","author":"Nangalia","year":"2017","journal-title":"Blood"},{"key":"10.1016\/bs.ircmb.2021.06.004_bb0480","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1182\/blood-2017-05-783225","article-title":"Clonal evolution and outcomes in myelofibrosis after ruxolitinib discontinuation","volume":"130","author":"Newberry","year":"2017","journal-title":"Blood"},{"key":"10.1016\/bs.ircmb.2021.06.004_bb0485","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1182\/blood-2014-04-569525","article-title":"Lysine-specific demethylase 1 (LSD1) in hematopoietic and lymphoid neoplasms","volume":"124","author":"Niebel","year":"2014","journal-title":"Blood"},{"key":"10.1016\/bs.ircmb.2021.06.004_bb0490","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1038\/leu.2016.32","article-title":"Thrombopoietin receptor is required for the oncogenic function of CALR mutants","volume":"30","author":"Nivarthi","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/bs.ircmb.2021.06.004_bb0495","doi-asserted-by":"crossref","first-page":"4214","DOI":"10.1182\/blood-2019-129254","article-title":"Molecular analysis in the pacritinib dose-finding PAC203 study in patients with myelofibrosis refractory or intolerant to ruxolitinib","volume":"134","author":"O'Sullivan","year":"2019","journal-title":"Blood"},{"key":"10.1016\/bs.ircmb.2021.06.004_bb0500","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1002\/cncr.32664","article-title":"Life after ruxolitinib: reasons for discontinuation, impact of disease phase, and outcomes in 218 patients with myelofibrosis","volume":"126","author":"Palandri","year":"2020","journal-title":"Cancer"},{"key":"10.1016\/bs.ircmb.2021.06.004_bb0505","doi-asserted-by":"crossref","first-page":"3472","DOI":"10.1182\/blood-2006-04-018879","article-title":"MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients","volume":"108","author":"Pardanani","year":"2006","journal-title":"Blood"},{"issue":"8","key":"10.1016\/bs.ircmb.2021.06.004_bb0510","doi-asserted-by":"crossref","first-page":"e335","DOI":"10.1038\/bcj.2015.63","article-title":"A phase 2 randomized dose-ranging study of the JAK2-selective inhibitor fedratinib (SAR302503) in patients with myelofibrosis","volume":"5","author":"Pardanani","year":"2015","journal-title":"Blood Cancer J."},{"key":"10.1016\/bs.ircmb.2021.06.004_bb0515","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1001\/jamaoncol.2015.1590","article-title":"Safety and efficacy of fedratinib in patients with primary or secondary myelofibrosis: a randomized clinical trial","volume":"1","author":"Pardanani","year":"2015","journal-title":"JAMA Oncol."},{"key":"10.1016\/bs.ircmb.2021.06.004_bb0520","doi-asserted-by":"crossref","first-page":"3676","DOI":"10.1182\/blood-2005-09-3826","article-title":"Relation between JAK2 (V617F) mutation status, granulocyte activation, and constitutive mobilization of CD34+ cells into peripheral blood in myeloproliferative disorders","volume":"107","author":"Passamonti","year":"2006","journal-title":"Blood"},{"key":"10.1016\/bs.ircmb.2021.06.004_bb0525","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1182\/blood-2008-10-183558","article-title":"Induction of myeloproliferative disorder and myelofibrosis by thrombopoietin receptor W515 mutants is mediated by cytosolic tyrosine 112 of the receptor","volume":"115","author":"Pecquet","year":"2010","journal-title":"Blood"},{"key":"10.1016\/bs.ircmb.2021.06.004_bb0530","doi-asserted-by":"crossref","first-page":"4625","DOI":"10.1182\/blood-2011-08-372524","article-title":"Thrombopoietin receptor down-modulation by JAK2 V617F: restoration of receptor levels by inhibitors of pathologic JAK2 signaling and of proteasomes","volume":"119","author":"Pecquet","year":"2012","journal-title":"Blood"},{"key":"10.1016\/bs.ircmb.2021.06.004_bb0535","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2018-99-118348","article-title":"Secreted mutant calreticulins as rogue cytokines trigger thrombopoietin receptor activation specifically in CALR mutated cells: perspectives for MPN therapy","author":"Pecquet","year":"2018"},{"key":"10.1016\/bs.ircmb.2021.06.004_bb0540","doi-asserted-by":"crossref","first-page":"2669","DOI":"10.1182\/blood-2018-09-874578","article-title":"Calreticulin mutants as oncogenic rogue chaperones for TpoR and traffic-defective pathogenic TpoR mutants","volume":"133","author":"Pecquet","year":"2019","journal-title":"Blood"},{"key":"10.1016\/bs.ircmb.2021.06.004_bb0545","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1182\/blood-2019-130046","article-title":"Final results of phase 2 clinical trial of LCL161, a novel oral SMAC mimetic\/IAP antagonist, for patients with intermediate to high risk myelofibrosis","volume":"134","author":"Pemmaraju","year":"2019","journal-title":"Blood"},{"issue":"15_Suppl","key":"10.1016\/bs.ircmb.2021.06.004_bb0550","doi-asserted-by":"crossref","first-page":"e19535","DOI":"10.1200\/JCO.2020.38.15_suppl.e19535","article-title":"Ruxolitinib (RUX) retreatment in patients (pts) with myelofibrosis (MF): real-world evidence on pt characteristics and outcomes","volume":"38","author":"Pemmaraju","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/bs.ircmb.2021.06.004_bb0555","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1182\/blood-2019-123244","article-title":"A phase 2a study of the LSD1 inhibitor Img-7289 (bomedemstat) for the treatment of myelofibrosis","volume":"134","author":"Pettit","year":"2019","journal-title":"Blood"},{"key":"10.1016\/bs.ircmb.2021.06.004_bb0560","doi-asserted-by":"crossref","first-page":"e270","DOI":"10.1371\/journal.pmed.0030270","article-title":"MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia","volume":"3","author":"Pikman","year":"2006","journal-title":"PLoS Med."},{"key":"10.1016\/bs.ircmb.2021.06.004_bb0565","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1016\/S1470-2045(17)30615-0","article-title":"Luspatercept for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes (PACE-MDS): a multicentre, open-label phase 2 dose-finding study with long-term extension study","volume":"18","author":"Platzbecker","year":"2017","journal-title":"Lancet Oncol."},{"key":"10.1016\/bs.ircmb.2021.06.004_bb0570","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1182\/blood-2017-10-810739","article-title":"Aggressive B-cell lymphomas in patients with myelofibrosis receiving JAK1\/2 inhibitor therapy","volume":"132","author":"Porpaczy","year":"2018","journal-title":"Blood"},{"key":"10.1016\/bs.ircmb.2021.06.004_bb0575","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aam7729","article-title":"Oncogenic JAK2(V617F) causes PD-L1 expression, mediating immune escape in myeloproliferative neoplasms","volume":"10","author":"Prestipino","year":"2018","journal-title":"Sci. Transl. Med."},{"issue":"22","key":"10.1016\/bs.ircmb.2021.06.004_bb0580","doi-asserted-by":"crossref","first-page":"e122703","DOI":"10.1172\/jci.insight.122703","article-title":"Targeting the CALR interactome in myeloproliferative neoplasms","volume":"3","author":"Pronier","year":"2018","journal-title":"JCI Insight"},{"key":"10.1016\/bs.ircmb.2021.06.004_bb0585","doi-asserted-by":"crossref","first-page":"3109","DOI":"10.1182\/blood-2009-04-214957","article-title":"Preclinical characterization of the selective JAK1\/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms","volume":"115","author":"Quint\u00e1s-Cardama","year":"2010","journal-title":"Blood"},{"key":"10.1016\/bs.ircmb.2021.06.004_bb0590","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1111\/j.1365-2141.2010.08266.x","article-title":"A pilot study of the histone-deacetylase inhibitor givinostat in patients with JAK2V617F positive chronic myeloproliferative neoplasms: givinostat treatment for CMNs","volume":"150","author":"Rambaldi","year":"2010","journal-title":"Br. J. Haematol."},{"issue":"22","key":"10.1016\/bs.ircmb.2021.06.004_bb0595","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2014-02-554634","article-title":"Integrated genomic analysis illustrates the central role of JAK-STAT pathway activation in myeloproliferative neoplasm pathogenesis","volume":"123","author":"Rampal","year":"2014","journal-title":"Blood"},{"key":"10.1016\/bs.ircmb.2021.06.004_bb0600","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1111\/bjh.14713","article-title":"Advances in understanding the pathogenesis of familial myeloproliferative neoplasms","volume":"178","author":"Rumi","year":"2017","journal-title":"Br. J. Haematol."},{"key":"10.1016\/bs.ircmb.2021.06.004_bb0605","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1038\/leu.2016.260","article-title":"BET protein bromodomain inhibitor-based combinations are highly active against post-myeloproliferative neoplasm secondary AML cells","volume":"31","author":"Saenz","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/bs.ircmb.2021.06.004_bb0610","doi-asserted-by":"crossref","first-page":"3956","DOI":"10.1182\/blood-2014-07-587238","article-title":"The thrombopoietin receptor, MPL, is critical for development of a JAK2V617F-induced myeloproliferative neoplasm","volume":"124","author":"Sangkhae","year":"2014","journal-title":"Blood"},{"key":"10.1016\/bs.ircmb.2021.06.004_bb0615","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/j.stem.2017.03.008","article-title":"Gli1+ mesenchymal stromal cells are a key driver of bone marrow fibrosis and an important cellular therapeutic target","volume":"20","author":"Schneider","year":"2017","journal-title":"Cell Stem Cell"},{"key":"10.1016\/bs.ircmb.2021.06.004_bb0620","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1056\/NEJMoa065202","article-title":"JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis","volume":"356","author":"Scott","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/bs.ircmb.2021.06.004_bb0625","doi-asserted-by":"crossref","first-page":"396","DOI":"10.3390\/cancers10110396","article-title":"Prolonged idasanutlin (RG7388) treatment leads to the generation of p53-mutated cells","volume":"10","author":"Skalniak","year":"2018","journal-title":"Cancer"},{"key":"10.1016\/bs.ircmb.2021.06.004_bb0630","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1002\/stem.2229","article-title":"P-selectin sustains extramedullary hematopoiesis in the gata1 low model of myelofibrosis","volume":"34","author":"Spangrude","year":"2015","journal-title":"Stem Cells (Dayton, Ohio)"},{"key":"10.1016\/bs.ircmb.2021.06.004_bb0635","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1007\/s10637-017-0495-3","article-title":"First-in-human study of the epichaperome inhibitor PU-H71: clinical results and metabolic profile","volume":"36","author":"Speranza","year":"2018","journal-title":"Invest. New Drugs"},{"key":"10.1016\/bs.ircmb.2021.06.004_bb0640","doi-asserted-by":"crossref","first-page":"4398","DOI":"10.1038\/emboj.2011.315","article-title":"Orientation-specific signalling by thrombopoietin receptor dimers","volume":"30","author":"Staerk","year":"2011","journal-title":"EMBO J."},{"key":"10.1016\/bs.ircmb.2021.06.004_bb0645","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1038\/nm.3512","article-title":"Transforming growth factor-\u03b2 superfamily ligand trap ACE-536 corrects anemia by promoting late-stage erythropoiesis","volume":"20","author":"Suragani","year":"2014","journal-title":"Nat. Med."},{"key":"10.1016\/bs.ircmb.2021.06.004_bb0655","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1200\/JCO.2010.29.8711","article-title":"Myeloproliferative neoplasms: molecular pathophysiology, essential clinical understanding, and treatment strategies","volume":"29","author":"Tefferi","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/bs.ircmb.2021.06.004_bb0650","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41375-020-0954-2","article-title":"Fedratinib, a newly approved treatment for patients with myeloproliferative neoplasm-associated myelofibrosis","volume":"35","author":"Talpaz","year":"2021","journal-title":"Leukemia"},{"key":"10.1016\/bs.ircmb.2021.06.004_bb0660","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1056\/NEJMoa1310523","article-title":"A pilot study of the telomerase inhibitor Imetelstat for myelofibrosis","volume":"373","author":"Tefferi","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/bs.ircmb.2021.06.004_bb0665","doi-asserted-by":"crossref","first-page":"3931","DOI":"10.1182\/blood-2007-08-107748","article-title":"Ratio of mutant JAK2-V617F to wild-type Jak2 determines the MPD phenotypes in transgenic mice","volume":"111","author":"Tiedt","year":"2008","journal-title":"Blood"},{"key":"10.1016\/bs.ircmb.2021.06.004_bb0670","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1182\/blood-2016-10-695940","article-title":"Genetic basis and molecular pathophysiology of classical myeloproliferative neoplasms","volume":"129","author":"Vainchenker","year":"2017","journal-title":"Blood"},{"key":"10.1016\/bs.ircmb.2021.06.004_bb0675","doi-asserted-by":"crossref","first-page":"82","DOI":"10.12688\/f1000research.13167.1","article-title":"JAK inhibitors for the treatment of myeloproliferative neoplasms and other disorders","volume":"7","author":"Vainchenker","year":"2018","journal-title":"F1000Res"},{"key":"10.1016\/bs.ircmb.2021.06.004_bb0680","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1056\/NEJMe1005856","article-title":"From palliation to targeted therapy in myelofibrosis","volume":"363","author":"Vannucchi","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/bs.ircmb.2021.06.004_bb0685","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1056\/NEJMoa1409002","article-title":"Ruxolitinib versus standard therapy for the treatment of polycythemia vera","volume":"372","author":"Vannucchi","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/bs.ircmb.2021.06.004_bb0690","doi-asserted-by":"crossref","first-page":"5487","DOI":"10.1182\/blood-2018-99-119428","article-title":"PD-1-mediated T cell exhaustion is prevalent among patients with MPN-associated myelofibrosis independent of JAK1\/2 inhibition","volume":"132","author":"Veletic","year":"2018","journal-title":"Blood"},{"key":"10.1016\/bs.ircmb.2021.06.004_bb0695","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1056\/NEJMoa1002028","article-title":"Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor in myelofibrosis","volume":"363","author":"Verstovsek","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/bs.ircmb.2021.06.004_bb0700","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1056\/NEJMoa1110557","article-title":"A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis","volume":"366","author":"Verstovsek","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/bs.ircmb.2021.06.004_bb0705","doi-asserted-by":"crossref","first-page":"5024","DOI":"10.1182\/blood-2009-05-222133","article-title":"Cotreatment with panobinostat and JAK2 inhibitor TG101209 attenuates JAK2V617F levels and signaling and exerts synergistic cytotoxic effects against human myeloproliferative neoplastic cells","volume":"114","author":"Wang","year":"2009","journal-title":"Blood"},{"key":"10.1016\/bs.ircmb.2021.06.004_bb0710","doi-asserted-by":"crossref","first-page":"3398","DOI":"10.1182\/blood-2015-10-674465","article-title":"A thrombopoietin receptor antagonist is capable of depleting myelofibrosis hematopoietic stem and progenitor cells","volume":"127","author":"Wang","year":"2016","journal-title":"Blood"},{"key":"10.1016\/bs.ircmb.2021.06.004_bb0715","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.leukres.2019.02.010","article-title":"Programmed cell death receptor (PD-1) ligand (PD-L1) expression in Philadelphia chromosome-negative myeloproliferative neoplasms","volume":"79","author":"Wang","year":"2019","journal-title":"Leuk. Res."},{"key":"10.1016\/bs.ircmb.2021.06.004_bb0720","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1126\/science.aaw3242","article-title":"Mechanism of homodimeric cytokine receptor activation and dysregulation by oncogenic mutations","volume":"367","author":"Wilmes","year":"2020","journal-title":"Science"},{"key":"10.1016\/bs.ircmb.2021.06.004_bb0725","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1182\/blood.V124.21.116.116","article-title":"Phase 1\/1b study of RG7388, a potent MDM2 antagonist, in acute myelogenous leukemia (AML) patients (pts)","volume":"124","author":"Yee","year":"2014","journal-title":"Blood"},{"key":"10.1016\/bs.ircmb.2021.06.004_bb0730","doi-asserted-by":"crossref","first-page":"539","DOI":"10.3109\/09537104.2013.840720","article-title":"Abnormal P-selectin localization during megakaryocyte development determines thrombosis in the gata1low model of myelofibrosis","volume":"25","author":"Zetterberg","year":"2013","journal-title":"Platelets"},{"key":"10.1016\/bs.ircmb.2021.06.004_bb0735","doi-asserted-by":"crossref","DOI":"10.1177\/2040620720906002","article-title":"Allogeneic hematopoietic stem-cell transplantation for myelofibrosis","volume":"11","author":"Zhang","year":"2020","journal-title":"Ther. Adv. Hematol."},{"key":"10.1016\/bs.ircmb.2021.06.004_bb0740","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1002\/iub.2198","article-title":"Novel targets to cure primary myelofibrosis from studies on gata1 low mice","volume":"72","author":"Zingariello","year":"2019","journal-title":"IUBMB Life"},{"key":"10.1016\/bs.ircmb.2021.06.004_bb0745","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1038\/nature10334","article-title":"RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia","volume":"478","author":"Zuber","year":"2011","journal-title":"Nature"}],"container-title":["International Review of Cell and Molecular Biology","Cellular and Molecular Aspects of Myeloproliferative Neoplasms \u2013 Part B"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1937644821000782?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1937644821000782?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T10:31:09Z","timestamp":1762597869000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1937644821000782"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022]]},"ISBN":["9780323899413"],"references-count":148,"URL":"https:\/\/doi.org\/10.1016\/bs.ircmb.2021.06.004","relation":{},"ISSN":["1937-6448"],"issn-type":[{"value":"1937-6448","type":"print"}],"subject":[],"published":{"date-parts":[[2022]]}}}